EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparison of Gene-Editing Approaches for Severe Congenital Neutropenia-Causing Mutations in the ELANE Gene

Malte Ulrich Ritter, Masoud Nasri, Benjamin Dannenmann, Perihan Mir, Benjamin Secker, Diana Amend, Maksim Klimiankou, Karl Welte, Julia Skokowa iD

The CRISPR Journal · 2024

DOI: 10.1089/crispr.2024.0006 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The CRISPR Journal, 2024. Verfasst von Malte Ulrich Ritter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Gene Editing, Neutropenia, Congenital Bone Marrow Failure Syndromes, CRISPR-Cas Systems. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Safety considerations for gene therapies of inherited preleukemia syndromes, including severe congenital neutropenia (CN), are paramount. We compared several strategies for CRISPR/Cas9 gene editing of autosomal-dominant ELANE mutations in CD34 + cells from two CN patients head-to-head. We tested universal and allele-specific ELANE knockout, ELANE mutation correction by homology-directed repair (HDR) with AAV6, and allele-specific HDR with ssODN. All strategies were not toxic, had at least 30% editing, and rescued granulopoiesis in vitro . In contrast to published data, allele-specific indels in the last exon of ELANE also restored granulopoiesis. Moreover, by implementing patient-derived induced pluripotent stem cells for GUIDE-Seq off-target analysis, we established a clinically relevant “personalized” assessment of off-target activity of gene editing on the background of the patient’s genome. We found that allele-specific approaches had the most favorable off-target profiles. Taken together, a well-defined head-to-head comparison pipeline for selecting the appropriate gene therapy is essential for diseases with several gene editing strategies available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingNeutropeniaCongenital Bone Marrow Failure SyndromesCRISPR-Cas SystemsGenetic TherapyMutationHumansAllelesInduced Pluripotent Stem CellsRecombinational DNA RepairLeukocyte Elastase

Substanzen

ELANE protein, humanLeukocyte Elastase

Autor:innen und Institutionen

  • Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
  • Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, University Hospital Tübingen, Tübingen, Germany.
  • Gene and RNA Therapy Center, Tübingen University, Tübingen, Germany.

ORCID-Profile: Julia Skokowa

Förderung

  • NIAID NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Ritter, M. U., Nasri, M., Dannenmann, B., Mir, P., Secker, B., Amend, D., Klimiankou, M., Welte, K., & Skokowa, J. (2024). Comparison of Gene-Editing Approaches for Severe Congenital Neutropenia-Causing Mutations in the ELANE Gene. The CRISPR Journal. https://doi.org/10.1089/crispr.2024.0006

Vancouver

Ritter MU, Nasri M, Dannenmann B, Mir P, Secker B, Amend D, et al. Comparison of Gene-Editing Approaches for Severe Congenital Neutropenia-Causing Mutations in the ELANE Gene. The CRISPR Journal. 2024. doi:10.1089/crispr.2024.0006

BibTeX
@article{Ritter2024,
  author = {Ritter, Malte Ulrich and Nasri, Masoud and Dannenmann, Benjamin and Mir, Perihan and Secker, Benjamin and Amend, Diana and Klimiankou, Maksim and Welte, Karl and Skokowa, Julia},
  title = {Comparison of Gene-Editing Approaches for Severe Congenital Neutropenia-Causing Mutations in the ELANE Gene},
  journal = {The CRISPR Journal},
  year = {2024},
  doi = {10.1089/crispr.2024.0006}
}
Kostenlos starten →